Helus Pharma Inc.
corporate_fare Company Profile
Helus Pharma Inc. (NASDAQ:HELP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 30 items for HELP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-27, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 14 rated 8 or above. Recent SEC coverage for HELP spans 6-K, 4, SCHEDULE 13D, 40-F.
Recent high-impact activity:
- Helus Pharma Co-Founders Exit Executive Roles; Mark Lawson Named Board Chair
- Helus Pivots HLP004 to GAD Monotherapy; APPROACH Phase 3 Data Still Due Q4 2026
- CFO Greg Cavers Buys $38,730 of Helus Pharma Stock at $12.91
- CEO Michael Halstead Buys $1.35M of Cybin Stock at $13.47
- Chief Growth Officer Adds $1.25M More — Third Purchase in Three Days
Financial Snapshot
Short Interest & Short Volume
1.95 days to coverFINRA reported short interest of 3,010,190 shares in HELP as of the October 15, 2026 settlement, a 13.1% decrease from the prior period — about 1.9 days to cover at its recent average daily volume. On October 30, 2026, 51.7% of HELP volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for HELP, detected from its recent SEC filings · based on capital-structure filings through 2026-06-25.
Underwritten Offering Priced · Substantial Share Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
HELP files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.